Home › Compare › ESTRF vs ABBV
ESTRF yields 20000000.00% · ABBV yields 3.06%● Live data
📍 ESTRF pulled ahead of the other in Year 1
Combined, ESTRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ESTRF + ABBV for your $10,000?
Estre Ambiental, Inc., a waste management company, provides a range of waste-related and environmental services for municipal, commercial, and industrial customers in Brazil and Latin America. The company operates through four segments: Collection & Cleaning Services, O&G, Landfill, and Value Recovery. The Collection & Cleaning Services segment is involved in the industrial collection from large businesses, as well as local household collection, transportation, and temporary storage for environmental liability emergencies and industrial accidents, as well as in the preparation of waste for final disposal. The O&G segment engages in the provision of soil treatment and restoration services; and cleaning of storage tanks for the oil and gas industry. The Landfill segment provides treatment and waste disposal services, such as ground sealing, drainage and treatment of percolated liquid, rainwater catchment, and soil treatment with hydrocarbons. The Value Recovery segment is involved in the provision of energy recycling services; and dismantlement of electrical-electronic products. The company also engages in the collection and burning of landfill biogas, and electricity generation businesses. In addition, it offers environmental consulting, laboratory analysis, environmental consulting, recycling, and energy use services. Estre Ambiental, Inc. was founded in 1999 and is headquartered in São Paulo, Brazil.
Full ESTRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.